2002-2006: ASAQ Development through Registration

In 2001 the World Health Organization recommended the use of four artemisinin-based combination therapies (ACTs), including the combination of AS+AQ. However, in the case of AS+AQ, there was neither a co-formulation nor any development partners.

The FACT (Fixed-Dose Artesunate Combination Therapy) project began in 2002 – under the umbrella of MSF (and then DNDi) in coordination with TDR- with the objective to develop a fixed-dose combination of AS+AQ that would improve compliance and would be available to all countries where resistance to amodiaquine was low (mainly African countries, but also some Asian countries like India and Indonesia)

Key partners included:

  • Centre National de Recherche et de Formation sur le Paludisme (CNRFP)
  • Instituto de Tecnologia em Fármacos of Farmanguinhos/Fiocruz
  • Mahidol University
  • Université Victor Segalen Bordeaux 2 (TROPIVAL),
  • University of Oxford
  • University Sains Malaysia
 2007-2009: Post-Registration Activities

DNDi plays an active role in facilitating FACT implementation by engaging partners such as pharmaceutical companies, national malaria programmes, research institutes, contract research organisations, and NGOs, as well as the WHO and TDR. DNDi convened an independent panel of experts, the FACT Implementation Advisory Group, who meets on an annual basis to provide external advice and critical guidance on development and facilitation of rational use and equitable access.
  more about the FACT Project for ASAQ